Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

Author： Davidson Michael H  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.5, Iss.1, 2006-01, pp. : 145-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus

By Reyes-Soffer Gissette   Rondon-Clavo Carlos   Ginsberg Henry N  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1429-1438

Informa Healthcare

Access to resources Recommend Favorite

Dyslipidaemia in diabetes: combination statin treatment an option

By  

Inpharma, Vol. 1, Iss. 1310, 2001-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Combination of Fenofibrate with Non-Statin Drug Regimens

By  

Current Pharmaceutical Design, Vol. 16, Iss. 30, 2010-10 ,pp. : 3401-3416

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic Interactions Between Herbal Medicines and Prescribed Drugs: Focus on Drug Metabolic Enzymes and Transporters

By  

Current Drug Metabolism, Vol. 15, Iss. 8, 2014-10 ,pp. : 791-807

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics and Metabolic Drug Interactions

By  

Current Clinical Pharmacology, Vol. 1, Iss. 1, 2006-01 ,pp. : 5-20

Bentham Science Publishers

Access to resources Recommend Favorite